Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RNXT
RNXT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RNXT News
RenovoRx Forms Medical Advisory Board to Enhance Oncology Strategies
5d ago
Newsfilter
RenovoRx Announces New Clinical Data Presentation
Feb 04 2026
Newsfilter
Oncolytics Biotech's Breakthroughs in Cancer Treatment
Jan 30 2026
PRnewswire
Oncolytics Biotech's Breakthroughs in Cancer Treatment
Jan 30 2026
Newsfilter
RenovoRx to Present New Research at 2026 SIO Meeting
Jan 28 2026
Newsfilter
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
Jan 12 2026
Benzinga
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
Jan 08 2026
Globenewswire
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
Jan 08 2026
Benzinga
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
Jan 08 2026
NASDAQ.COM
Novo Nordisk (NVO) Gains 9.48% After FDA Approves Wegovy Obesity Pill
Dec 23 2025
NASDAQ.COM
After-Hours Gains on Friday: Biotech and Genomics Stocks Demonstrate Resilience
Dec 22 2025
NASDAQ.COM
Repare Surges 30%, Nuvalent Rises 9% in After-Hours Biotech Gains
Nov 17 2025
NASDAQ.COM
RenovoRx CEO Shaun Bagai to Speak at Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum on November 20th
Nov 04 2025
Newsfilter
Natural Killer Cell Treatments Drive $254B Shift in Immunotherapy Market
Oct 17 2025
Newsfilter
RenovoRx Enhances Scientific Advisory Board by Adding Esteemed Interventional Oncologist Thierry de Baère, MD, PhD
Oct 09 2025
Newsfilter
RenovoRx's PanTheR Post-Marketing Registry Study Advances with Initial Clinical Procedure and Inclusion of Two New Clinical Sites
Sep 25 2025
Newsfilter
Show More News
